Results 281 to 290 of about 2,291,402 (391)

Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient [PDF]

, 2003
Pritesh J. Gandhi, Pearl A. Menezes, Hien Vu, Amy L. Rivera, Karthik Ramaswamy   +4 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Droplet-Based Measurements of DNA-Templated Nanoclusters-Towards Point-of-Care Applications. [PDF]

Biosensors (Basel)
Kluitmann J, Di Fiore S, Nölke G, Drese KS.   +3 more
europepmc   +1 more source

Opinions on changes in the Romanian health care system from people's point of view: a descriptive study [PDF]

, 2003
A.-C. Bara, W.J.A. van den Heuvel, J.A.M. Maarse, Jitse P. van Dijk, Luc de Witte   +4 more
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions

FEBS Open Bio, EarlyView.
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik, Deniz Bakkalci, Alexander J. MacRobert, Umber Cheema   +3 more
wiley   +1 more source

IoMT Architecture for Fully Automated Point-of-Care Molecular Diagnostic Device. [PDF]

Sensors (Basel)
Kim MG, Kil BH, Ryu MH, Kim JD.
europepmc   +1 more source

An efficient strategy for producing RNA‐free Nucleocapsid protein of SARS‐CoV‐2 for biochemical and structural investigations

FEBS Open Bio, EarlyView.
Cleavable N‐terminal Thioredoxin fusion enabled soluble expression and purification of otherwise insoluble SARS‐CoV‐2 Nucleocapsid (N) protein. A four‐step purification strategy yielded highly homogeneous, RNA‐free N protein. Binding assays showed high RNA affinity (Kd ~ 28 nm). The study will facilitate high‐resolution structural studies of N protein,
Shweta Singh, Gagan D. Gupta
wiley   +1 more source

The Expanding Point of Care Ultrasound (POCUS) Paradigm. [PDF]

POCUS J
Wiskar K.
europepmc   +1 more source